| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Human JF 305 pancreatic cancer cells and MCF-7 breast cancer cells xenografted into zebrafish respond well to furadienes (1.4, 4.1, 12.2 uM; 48 hours) [1]. The expression of the Pgp-related gene (MDR1) is unaffected by furandadiene [1].
- Anti-proliferative activity: Furanodiene inhibited the proliferation of lung cancer cells (A549, NCI-H1299, 95-D) in a concentration-dependent manner, with IC50 values ranging from 10 to 30 μM. It also suppressed colony formation in A549 and 95-D cells . - Induction of endoplasmic reticulum (ER) stress: Furanodiene upregulated the mRNA and protein expression levels of binding immunoglobulin protein (BiP) and C/EBP homologous protein (CHOP), indicating ER stress induction. Nuclear accumulation of CHOP further confirmed this effect . - Synergistic effects with paclitaxel: Combined treatment with paclitaxel showed significant synergy in NCI-H1299 and 95-D cells, suggesting potential for combination therapy . |
|---|---|
| ln Vivo |
- Antitumor activity in zebrafish models: Furanodiene reduced tumor growth in zebrafish models, potentially through mechanisms involving cytokine gene stimulation (e.g., upregulation of IL-1α, IL-1β, IL-6, TNF-α, and IFN-γ; downregulation of IL-4, IL-5, IL-10, and TGF-β) .
- Toxicity assessment: No significant adverse effects were observed in zebrafish at doses up to 90 μg/g .
|
| Cell Assay |
- MTT and apoptosis assays: Furanodiene induced apoptosis in lung cancer cells, as demonstrated by increased caspase-3/7 activity and Annexin V staining .
- Western blot and PCR analysis: Upregulation of ER stress markers (BiP, CHOP) and downregulation of anti-apoptotic proteins (Bcl-2) were observed .
|
| Animal Protocol |
- Zebrafish model: Furanodiene was administered by immersion in the water at concentrations of 10-90 μg/g. Tumor growth was assessed by visual inspection and histological analysis .
- Solubility and formulation: Furanodiene was dissolved in DMSO and diluted in fish water to achieve the desired concentrations .
|
| ADME/Pharmacokinetics |
Metabolism: Furandiene is primarily metabolized by cytochrome P450 enzymes (mainly CYP2E1) to produce reactive intermediates, such as cis-2-buten-1,4-dialdehyde (BDA). These metabolites may be associated with its toxicity and anticancer effects. - Tissue Distribution: Rodent studies have shown that furans (a related compound) preferentially accumulate in the liver, kidneys, and heart, with lower concentrations in the lungs and blood.
|
| Toxicity/Toxicokinetics |
Metabolism: Furandiene is primarily metabolized by cytochrome P450 enzymes (mainly CYP2E1) to produce reactive intermediates, such as cis-2-buten-1,4-dialdehyde (BDA). These metabolites may be associated with its toxicity and anticancer effects. - Tissue Distribution: Rodent studies have shown that furans (a related compound) preferentially accumulate in the liver, kidneys, and heart, with lower concentrations in the lungs and blood.
|
| References | |
| Additional Infomation |
Furandiene is a sesquiterpene compound. It has been reported in turmeric, Cyperus rotundus, and other organisms with relevant data. See also: Furandiene (note moved here). - Natural Source: Furandiene is a sesquiterpene compound isolated from the traditional Chinese medicine Cuscuta chinensis (turmeric). - Mechanism of Action: In addition to inducing endoplasmic reticulum stress, furandiene may also exert its effects by regulating cytokine signaling and immune responses. - Therapeutic Potential: Furandiene shows potential as an anticancer drug, especially when used in combination with other therapies, but further preclinical and clinical studies are needed to validate its efficacy and safety.
|
| Molecular Formula |
C15H20O
|
|---|---|
| Molecular Weight |
216.3187
|
| Exact Mass |
216.151
|
| Elemental Analysis |
C, 83.28; H, 9.32; O, 7.40
|
| CAS # |
19912-61-9
|
| PubChem CID |
636458
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
0.945±0.06 g/cm3
|
| Boiling Point |
309.6±11.0 °C at 760 mmHg
|
| Melting Point |
74-75 °C
|
| LogP |
4.359
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C/1=C\CC2=C(C/C(=C/CC1)/C)OC=C2C
|
| InChi Key |
VMDXHYHOJPKFEK-IAVOFVOCSA-N
|
| InChi Code |
InChI=1S/C15H20O/c1-11-5-4-6-12(2)9-15-14(8-7-11)13(3)10-16-15/h6-7,10H,4-5,8-9H2,1-3H3/b11-7+,12-6+
|
| Chemical Name |
(5E,9E)-3,6,10-trimethyl-4,7,8,11-tetrahydrocyclodeca[b]furan
|
| Synonyms |
Furanodiene; G0AFT38FJ7; 19912-61-9; DTXSID401319109; (5E,9Z)-3,6,10-Trimethyl-4,7,8,11-tetrahydrocyclodeca[b]furan; Germacra-1(10),4,7,11-tetraene, 8,12-epoxy-, (Z,E)-; Cyclodeca(b)furan, 4,7,8,11-tetrahydro-3,6,10-trimethyl-, (5E,9Z)-; (5E,9Z)-3,6,10-trimethyl-4,7,8,11-tetrahydrocyclodeca(b)furan;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6228 mL | 23.1139 mL | 46.2278 mL | |
| 5 mM | 0.9246 mL | 4.6228 mL | 9.2456 mL | |
| 10 mM | 0.4623 mL | 2.3114 mL | 4.6228 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
